Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Harold N Keer, MD, PhD
Astex Pharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
95 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Az Sint-Jan Brugge-Oostende Av
Bruges, Belgium
- Cliniques Universitaires Saint-Luc
Brussels, Belgium
- Universitair Ziekenhuis Gent
Ghent, Belgium
- Tom Baker Cancer Centre
Calgary, Alberta, Canada
- University of Alberta Hospital
Edmonton, Alberta, Canada
- Princess Margaret Cancer Centre
Toronto, Ontario, Canada
- Mcgill University Health Centre
Montreal, Quebec, Canada
- Hopital Maisonneuve Rosemont
Montreal, Canada
- Aarhus University Hospital
Aarhus C, Denmark
- Rigshospitalet
Copenhagen, Denmark
- Centre Hospitalier de la Côte Basque
Bayonne, France
- Hôpital de la Conception
Marseille, France
- Chru Montpellier - Saint Eloi
Montpellier, France
- Groupe Hospitalier de la Région de Mulhouse Et Sud Alsace
Mulhouse, France
- Hôpital Saint-Louis
Paris, France
- Chu Hopitaux de Bordeaux - Hôpital Haut-Lévêque
Pessac, France
- Centre Hospitalier Lyon-Sud
Pierre-Bénite, France
- Centre Henri Becquerel
Rouen, France
- Institut Universitaire Du Cancer de Toulouse - Oncopole
Toulouse, France
- Universitätsklinikum Leipzig
Leipzig, Saxony, Germany
- Städtisches Klinikum Braunschweig Ggmbh
Braunschweig, Germany
- Marien Hospital Düsseldorf Gmbh
Düsseldorf, Germany
- Universitätsklinikum Halle (saale)
Halle, Germany
- Universitätsklinikum Schleswig-Holstein
Kiel, Germany
- Medizinischen Fakultät Mannheim Der Universität Heidelberg
Mannheim, Germany
- Klinikum Der Universität München
München, Germany
- Universitätsklinikum Ulm
Ulm, Germany
- Se Áok I. Sz. Belgyógyászati Klinika
Budapest, Hungary
- Debreceni Egyetem Klinikai Központ
Debrecen, Hungary
- Somogy Megyei Kaposi Mór Oktató Kórház
Kaposvár, Hungary
- Pecsi Tudomanyegyetem Klinikai Központ
Pécs, Hungary
- Szegedi Tudományegyetem
Szeged, Hungary
- Irccs Aou San Martino - Ist
Genova, Italy
- Fondazione Irccs Cà Granda Ospedale Maggiore Policlinico
Milan, Italy
- Ospedale San Raffaele - Milano
Milan, Italy
- A.O.R.N. "a. Cardarelli"
Naples, Italy
- A.S.U Integrata Di Udine - Presidio Ospedaliero Santa Maria Della Misericordia
Udine, Italy
- Akita University Hospital
Akita, Japan
- Chugoku Central Hospital
Fukuyama-Shi, Japan
- Tokai University Hospital
Isehara-shi, Japan
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 16 Mar 2017
- Primary completion
- 20 Jan 2020
- Completion
- 1 Jun 2020
- Last update posted
- 28 Aug 2024
- Registered enrollment
- 302
- Registry id
- NCT02920008
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.